Neurology Perspective

 
 

  • Transplant Centers Often Skip the Top Spot on the Kidney Waitlist   How donor kidneys are allocated to waiting patients isn't as straightforward as it might seem.
  • Game-Changing Alzheimer’s Research: The Latest on Biomarkers Dr Bradford Dickerson discusses the current framework for defining Alzheimer’s disease biologically, and the potential for emerging plasma biomarkers.
  • From ECCMID: New Anti-Viral and Bacterial Drugs of Interest   Infectious disease expert Dr Paul Auwaerter discusses news from ECCMID, including data on invasive group A streptococcus infections, and the new drugs ensitrelvir, gepotidacin, and sulbactam-durlobactam.
  • Medscape Physician Assistant Compensation Report 2023 Physician assistants (PAs) seem increasingly dissatisfied with their compensation, even though it rose last year. Gender and age made a difference, with male and older PAs earning more on average.
  • Jun 02, 2023 This Week in Cardiology   Listener feedback on the most important study in a decade, MONITOR-HF, a flawed paper and analysis, and the tension between pathos and logos are the topics John Mandrola, MD discusses in this week's podcast.
  • Is the Field of Electrophysiology Stuck? The 2023 Heart Rhythm Society meeting featured hot topics such as pulsed-field ablation and late-breaking "trials" on conduction system pacing, but the data gave this electrophysiologist pause.
  • COVID Boosters Effective, but Not for Long   Dr F. Perry Wilson explains a unique study design that helps answer questions about the effectiveness of COVID booster vaccines.
  • May 26 2023 This Week in Cardiology   An HRS meeting recap, Impella failure, sacubitril/valsartan, the purpose of trials, and a major breakthrough in evidence generation are the topics discussed by John Mandrola, MD in this week's podcast.
  • A Glimpse of Hope in Alzheimer's Disease?   Neurologist Hans-Christoph Diener reviews the data on new monoclonal therapies that bring hope to the treatment of Alzheimer's disease.
  • Alzheimer's Disease Highlights From AAN 2023   Highlights in Alzheimer's disease (AD) presented at AAN 2023 focus on amyloid-lowering therapies in early AD, 12-month results of ALZ-801, and ALZ-NET, a national registry that benefits AD research.
  • To Cease or Not to Cease Anticoagulation After AF Ablation The debate around anticoagulation post-AF ablation revolves around striking the delicate balance between preventing strokes and minimizing bleeding risks. In comparing study outcomes, we will explore the ongoing investigation of how to optimally treat patients.
  • Medscape Neurologist Compensation Report 2023 Is neurologists' income trending in the right direction? Do they feel fairly paid and would they choose a medical career again? Our 2023 Neurologist Compensation Report gives the answers.
  • Ketamine, Pain, and Depression: A Special Connection   Ketamine may be a potent analgesic, but its effects on chronic pain may have more to do with its antidepressant effects, according to a recent study. F. Perry Wilson comments.
  • S2 Episode 4: Schizophrenia, Clinical High-risk Syndrome, and Psychosis   Drs John M. Kane and Scott W. Woods discuss clinical high-risk syndrome and schizophrenia, including assessment methods, interventions, and risk indicators for future psychosis.
  • Prior-Authorization Woes? These Tools May Change the Game   Alok S. Patel, MD, discusses prior authorizations and the potential use of artificial intelligence.
  • May 19 2023 This Week in Cardiology   When to use an ICD, risk stratification for HCM, blending EP and structural cardiology to improve care in post-TAVI patients, and hsTroponins are the topics John Mandrola, MD, discusses in this week’s podcast.
  • Best & Worst Places to Practice 2023 Check out our 2023 choices for the best and worst communities, based on such factors as income, malpractice climate, lifestyle, and health indicators.
  • Top 5 Movement Disorders Highlights From AAN 2023   Kathrin LaFaver discusses the movement disorders presentations that piqued her interest at the 2023 American Academy of Neurology meeting with fellow neurologist Indu Subramanian.
  • What to Expect in the New Concussion Guidelines   Andrew N. Wilner, MD, and Shae Datta, MD, discuss recent developments in sports neurology.
  • The BOX Trial: Do Higher Blood Pressure Targets After Cardiac Arrest Improve Outcomes? This review explores outcomes of the BOX trial, which found that targeting a mean arterial blood pressure of 77 mm Hg or 63 mm Hg in patients who had been resuscitated from cardiac arrest did not result in significantly different percentages of patients dying or having severe disability or coma.